- Home
- BWLP vs ETNB Comparison
BWLP vs ETNB Comparison
Compare BWLP & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWLP
- ETNB
- Stock Information
- Founded
- BWLP 1935
- ETNB 2018
- Country
- BWLP Singapore
- ETNB United States
- Employees
- BWLP N/A
- ETNB N/A
- Industry
- BWLP Marine Transportation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- BWLP Consumer Discretionary
- ETNB Health Care
- Exchange
- BWLP Nasdaq
- ETNB Nasdaq
- Market Cap
- BWLP 2.4B
- ETNB 2.2B
- IPO Year
- BWLP N/A
- ETNB 2019
- Fundamental
- Price
- BWLP $12.90
- ETNB $14.84
- Analyst Decision
- BWLP
- ETNB Buy
- Analyst Count
- BWLP 0
- ETNB 10
- Target Price
- BWLP N/A
- ETNB $22.31
- AVG Volume (30 Days)
- BWLP 413.1K
- ETNB 3.6M
- Earning Date
- BWLP 11-27-2025
- ETNB 11-07-2025
- Dividend Yield
- BWLP 10.39%
- ETNB N/A
- EPS Growth
- BWLP N/A
- ETNB N/A
- EPS
- BWLP 1.50
- ETNB N/A
- Revenue
- BWLP $3,554,740,000.00
- ETNB N/A
- Revenue This Year
- BWLP N/A
- ETNB N/A
- Revenue Next Year
- BWLP $3.46
- ETNB N/A
- P/E Ratio
- BWLP $8.93
- ETNB N/A
- Revenue Growth
- BWLP 1.27
- ETNB N/A
- 52 Week Low
- BWLP $7.86
- ETNB $4.16
- 52 Week High
- BWLP $16.60
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- BWLP 45.26
- ETNB 76.55
- Support Level
- BWLP $12.42
- ETNB $14.74
- Resistance Level
- BWLP $12.87
- ETNB $14.85
- Average True Range (ATR)
- BWLP 0.35
- ETNB 0.06
- MACD
- BWLP 0.09
- ETNB -0.19
- Stochastic Oscillator
- BWLP 72.13
- ETNB 66.67
About BWLP BW LPG Limited Common Shares
BW LPG Ltd is an LPG shipping. It uses pioneering technology to power its vessels with cleaner-burning liquefied petroleum gas (LPG) and invest in R&D to take towards a zero-carbon future. The company is organized into two main segments: The shipping segment and the product services segment which buy and sell liquid petroleum gas and deliver it to customers. It generates the majority of its revenue from the shipping segment.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).